Stocks of the Hour: PharmAust, Impact Minerals, Peregrine Gold
Stocks of the Hour: PharmAust, Impact Minerals, Peregrine Gold
To register for today's webinar click here.
要注册今天的网络研讨会，请单击此处。
PharmAust (ASX:PAA & PAAOA) announced it has received Orphan Drug Designation (ODD) from the United States Food and Drug Administration for monepantel and its treatment of Motor Neurone Disease (MND). PharmAust's application was based on preclinical mechanistic data that demonstrates MPL can induce autophagy in diseased cells, and consideration of the pathology of the disease. Shares are trading 13.51 per cent higher at 21 cents.
PharmAust（澳大利亚证券交易所股票代码：PAA和PAAOA）宣布，其莫奈太尔及其运动神经元疾病（MND）治疗已获得美国食品药品监督管理局颁发的孤儿药认证（ODD）。PharmAust 的应用基于临床前机制数据，这些数据表明 MPL 可以诱发患病细胞的自噬，并考虑了该疾病的病理。股价上涨13.51％，至21美分。
Impact Minerals (ASX:IPT) has raised $3 million via a strategic placement to fund the Pre-Feasibility Study at their Hope High Purity Alumina Project. $500,000 of that will be used for exploration activities at the Arkun Project. Shares are trading 9.09 per cent lower at 2 cents.
Impact Minerals（澳大利亚证券交易所股票代码：IPT）已通过战略配售筹集了300万美元，为其Hope高纯氧化铝项目的预可行性研究提供资金。其中50万美元将用于Arkun项目的勘探活动。股价下跌9.09％，至2美分。
Peregrine Gold (ASX:PGD) has announced that drilling is commencing at the Tin Can Prospect in WA. Initial drilling is planned to extend the mineralisation down plunge, followed by drilling along strike across the broader Tin Can gold in soil anomaly. Shares are flat at 29 cents.
Peregrine Gold（澳大利亚证券交易所股票代码：PGD）宣布，正在西澳大利亚州的锡罐勘探区开始钻探。最初的钻探计划将矿化向下延伸，然后沿着走向钻探到更广泛的土壤异常中的锡罐金。股价持平至29美分。
